

英文影印版

Owen □ Pereira □ Sayegh

透析与移植 Dialysis and Transplantation



A COMPANION TO
Brenner & Rector's THE KIDNEY

科学出版社 ☆ Harcourt Asia ☆ W.B.Saunders

英 文 影 印 版

透 析 与 肾 植

《布伦纳-雷克托肾脏病学》配套用书

Dialysis and Transplantation

William F. Owen, Jr., MD

Brian J. G. Pereira, MD, DM

Mohamed H. Sayegh, MD



科 学 出 版 社

Harcourt Asia

W. B. Saunders

2 0 0 1

William F. Owen, Brian J. G. Pereira, Mohamed H. Sayegh: Dialysis and Transplantation, 1st Edition

Copyright © 2000 **Harcourt Publishers Limited.**

Authorized Reprinting by **Science Press**, A division of *China Science Publishing Group*.

All rights reserved. For sale in the People's Republic of China only.

Reprint ISBN 0-8089-2212-2

本书英文影印版由科学出版社——中国科学出版集团核心企业和美国哈克出版集团国际公司合作出版。本版本是最新美国版,惟一获正式授权的完整和无节略的复制版,仅限在中国境内(不包括香港特别行政区和台湾省)出版和标价销售。
未经出版者书面许可,不得以任何方式复制或抄袭本书的任何部分。

版权所有,翻印必究。

北京市版权局版权登记号:01-2000-2847

图书在版编目(CIP)数据

透析与移植:英文影印版/(美)欧文(Owen, W. F.)主编. -北京:科学出版社,2001.1

书名原文:Dialysis and Transplantation

ISBN 7-03-008824-7

I. 透… II. 欧… III. ①肾疾病-透析疗法②肾-移植术(医学) IV. R692

中国版本图书馆 CIP 数据核字(2000)第 69921 号

注 意

医学是一门不断发展的科学。由于新的研究及临床实践在不断丰富人们的知识,因此在药物使用及治疗方面也在谋求各种变化。本书编者及出版者核对了各种信息来源,并确信本书内容完全符合出版时的标准。然而,鉴于不可避免的人为错误和医学学科的发展,不管是编者、出版者还是其他参与本书出版的工作者均不能保证此书中的内容百分之百正确。因此,他们不能对由此类错误引起的后果负责。

我们提倡读者将本书内容与其他资料进行确证。例如,我们希望读者对他们将要使用的每一种药品的说明书仔细阅读,以确证本书的有关信息是正确的,且推荐的药品用量及禁忌证等没有变化。该建议对新药或非常用药尤为重要。

科学出版社 出版

北京东黄城根北街16号
邮政编码:100717

新蕾印刷厂印刷

科学出版社发行 各地新华书店经销

*

2001年1月第 一 版 开本:889×1194 1/16

2001年1月第一次印刷 印张:43 3/4 插页:2

印数:1—3 000 字数:1 516 000

定价: 98.00 元

(如有印装质量问题,我社负责调换〈新欣〉)

Dialysis and Transplantation

A Companion to
Brenner & Rector's THE KIDNEY

William F. Owen, Jr., M.D.

Director
Duke Institute of Renal Outcomes Research and Health Policy
Duke Clinical Research Institute
Division of Nephrology
Duke University Medical Center
Durham, North Carolina

Brian J. G. Pereira, M.D., D.M.

Vice Chairman, Department of Medicine
Professor of Medicine
Tufts University School of Medicine
Staff Physician, Division of Nephrology
New England Medical Center
Boston, Massachusetts

Mohamed H. Sayegh, M.D.

Associate Professor of Medicine
Harvard Medical School
Research Director
Laboratory of Immunogenetics and Transplantation
Brigham and Women's Hospital
Boston, Massachusetts

SCIENCE PRESS
HARCOURT ASIA
W. B. SAUNDERS

SCIENCE PRESS

A division of China Science Publishing Group
16 Donghuangchenggen North Street,
Beijing 100717
China

HARCOURT ASIA PTE. LTD

A Harcourt Publishers International
Company.
583 Orchard Road #09-01 Forum
Singapore 238884

Distribute in the Mainland China by Science Press,
16 Donghuangchenggen North Street, Beijing 100717, China.

Copyright © 2000 by W. B. Saunders

All rights reserved. No part of this publication may be reproduced, or transmitted in any form of by any means, electronic, mechanical, including photocopy, recording or any information storage and retrieval system, without permission in writing from the publisher.

Printed in China by HARCOURT ASIA PTE, LTD and SCIENCE PRESS under special arrangement with W. B. Saunders, A Harcourt Health Science Company. This edition is the only authorized complete and unabridged reproduction of the latest American Edition, published and priced for sale in China only, not including Hong Kong SAR and Taiwan.

Unauthorized export of this edition is a violation of the Copyright Act Violation of this Law is subject to Civil and Criminal penalties.

This Edition First Printed in China in 2001.

ISBN 7-03-008824-7/R • 605

Reprint ISBN 0-8089-2212-2

Printed in China

To my wife, children, and teachers
William F. Owen, Jr.

*To my wife, Sunita,
and children, Natasha and Nikhil,
for their constant support and understanding*

*To my mentors,
Drs. Kirpal Chugh, Nicolaos Madias,
and Andrew Levey
Brian J. G. Pereira*

*To my two brothers,
Dr. Sard H. Sayegh and Abdul Hafiz H. Sayegh,
for their continuous support of my career
through the years
Mohamed H. Sayegh*

NOTICE

Medicine is an ever-changing field. Standard safety precautions must be followed, but as new research and clinical experience broaden our knowledge, changes in treatment and drug therapy become necessary or appropriate. Readers are advised to check the product information currently provided by the manufacturer of each drug to be administered to verify the recommended dose, the method and duration of administration, and the contraindications. It is the responsibility of the treating physician, relying on experience and knowledge of the patient, to determine dosages and the best treatment for the patient. Neither the Publisher nor the editor assumes any responsibility for any injury and or damage to persons or property.

THE PUBLISHER

CONTRIBUTORS

Steven R. Alexander, M.D.

Professor of Pediatrics, Stanford University School of Medicine; Chief, Nephrology, Stanford University Medical Center, Stanford; Medical Director, Dialysis and Renal Transplantation, Lucille Salter Packard Children's Hospital at Stanford, Palo Alto, California
Pediatric Dialysis

Ahmed M. Alkhunaizi, M.D.

Fellow, Transplant Medicine, Oregon Health Sciences University School of Medicine, Portland, Oregon; Attending Physician, Nephrology/Renal Transplantation, Dhahran Health Center, Dhahran, Saudi Arabia
Induction Immunosuppressive Therapy

Miriam J. Alter, Ph.D.

Chief, Epidemiology Section, Hepatitis Branch, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
Nosocomial Infections in Hemodialysis Units: Strategies for Control

Matthew J. Arduino, Dr.P.H.

Chief, Dialysis and Medical Devices Section, Hospital Infection Program, Centers for Disease Control and Prevention, Atlanta, Georgia
Nosocomial Infections in Hemodialysis Units: Strategies for Control

George R. Aronoff, M.D., F.A.C.P.

Professor of Medicine and Pharmacology and Chief, Division of Nephrology, University of Louisville School of Medicine, Louisville, Kentucky
Drug Dosing in Dialysis Patients

Peter G. Blake, M.B., F.R.C.P.C.

Associate Professor, University of Western Ontario, Faculty of Medicine; Staff Nephrologist, Director of Peritoneal Dialysis and Co-Director, Optimal Dialysis Research Unit, London Health Sciences Centre, London, Ontario, Canada
Peritoneal Dialysis Prescription: Dosing and Adequacy

Joan Blondin, M.D.

Clinical Professor of Medicine, Louisiana State University School of Medicine in Shreveport; Director, Physicians Information Exchange, Inc., Shreveport, Louisiana
Algorithms and Care Paths for Quality Improvement

Hugh R. Brady, M.D., Ph.D., F.R.C.P.I.

Professor of Medicine and Therapeutics, University College Dublin; Mater Misericordiae Hospital, Dublin, Ireland
Dopamine, Atrial Natriuretic Peptide, and Growth Factors in Acute Renal Failure; Recurrent and De Novo Renal Disease in Kidney Transplantation

Michael E. Brier, Ph.D.

Associate Professor of Medicine, University of Louisville School of Medicine, Louisville, Kentucky
Drug Dosing in Dialysis Patients

Charles B. Carpenter, M.D.

Professor in Medicine, Harvard Medical School; Attending Physician, Brigham and Women's Hospital, Boston, Massachusetts
Current Results and Determinants of Graft Outcome in Kidney Transplantation

Glenn M. Chertow, M.D., M.P.H.

Assistant Professor of Medicine, University of California, San Francisco, School of Medicine and UCSF Medical Center, San Diego, California
Selection of Dialysis Modality

Alfred K. Cheung, M.D.

Professor of Medicine, University of Utah School of Medicine; Chief, Dialysis, Veterans Affairs Medical Center, Salt Lake City, Utah
Biocompatibility of Hemodialysis Membranes

David N. Churchill, M.D., F.R.C.P.C.

Professor of Medicine, McMaster University, Faculty of Health Sciences; Attending Physician, St. Joseph's Hospital, Hamilton, Ontario, Canada
Peritoneal Dialysis Prescription: Dosing and Adequacy

Michael Clarkson, M.B., M.R.C.P.I.

Lecturer in Medicine, University College Dublin; Mater Misericordiae Hospital, Dublin, Ireland
Dopamine, Atrial Natriuretic Peptide, and Growth Factors in Acute Renal Failure

Patrick L. Coleman, M.B., M.R.C.P.I.

Lecturer in Medicine, University College Dublin; Mater Misericordiae Hospital, Dublin, Ireland
Dopamine, Atrial Natriuretic Peptide, and Growth Factors in Acute Renal Failure

Peter J. Conlon, M.B., M.H.S., F.A.C.P., F.R.C.P.I.
Consultant Nephrologist/Renal Transplant Physician,
Department of Nephrology, Beaumont Hospital, Dublin,
Ireland; Consulting Assistant Clinical Professor of
Medicine, Duke University School of Medicine,
Durham, North Carolina
Vascular Access for Hemodialysis

Gabriel M. Danovitch, M.D.
Professor of Medicine, University of California, Los
Angeles, UCLA School of Medicine; Medical Director,
Kidney Transplant Program, UCLA Medical Center, Los
Angeles, California
Diagnosis and Therapy of Graft Dysfunction

Francis L. Delmonico, M.D.
Associate Professor of Surgery, Harvard Medical School;
Visiting Surgeon and Director of Renal Transplantation,
Massachusetts General Hospital, Boston, Massachusetts;
Medical Director, New England Organ Bank, Newton,
Massachusetts
Surgical Aspects of Renal Transplantation

Mark D. Denton, M.B., M.R.C.P.
Instructor in Medicine, Harvard Medical School;
Clinical Fellow, Brigham and Women's Hospital, Boston,
Massachusetts
Dopamine, Atrial Natriuretic Peptide, and Growth Factors
in Acute Renal Failure

Thomas A. Depner, M.D.
Professor of Medicine, University of California, Davis,
School of Medicine, Davis; Director of Dialysis Services,
University of California, Davis, Medical Center,
Sacramento, California
Principles of Hemodialysis

Karen M. Erbeck, M.D.
Associate Professor of Medicine and Director, Home
Dialysis Training Unit, University of Louisville School of
Medicine, Louisville, Kentucky
Drug Dosing in Dialysis Patients

Harold I. Feldman, M.D., M.S.
Assistant Professor of Medicine and Epidemiology,
Renal, Electrolyte and Hypertension Division,
Department of Medicine and Department of
Biostatistics and Epidemiology, Center for Clinical
Epidemiology and Biostatistics, University of
Pennsylvania School of Medicine, Philadelphia,
Pennsylvania
Reprocessing of Hemodialyzers

M. Roy First, M.D.
Professor of Medicine, University of Cincinnati College
of Medicine; Director, Section of Transplantation,
University Hospital, Cincinnati, Ohio
Medical Complications of Kidney Transplantation

Robert N. Foley, M.B., F.R.C.P.(C.)
Associate Professor of Medicine, Memorial University of
Newfoundland Faculty of Medicine; Staff Nephrologist,
Health Care Corporation of St. John's Hospital, St.
John's, Newfoundland, Canada
Cardiac Disease in Dialysis Patients

Ram Gokal, M.D., F.R.C.P.
Honorary Reader, University of Manchester; Consultant
Nephrologist, Manchester Royal Infirmary, Manchester,
United Kingdom
Management of Peritoneal Dialysis Infections

Thomas A. Golper, M.D., F.A.C.P.
Professor of Medicine, University of Arkansas College of
Medicine (for Medical Sciences), Little Rock, Arkansas;
Chief Medical Officer, Renal Disease Management, Inc.,
Youngstown, Ohio
Extracorporeal Treatment of Poisoning

Simin Goral, M.D.
Assistant Professor of Medicine, Vanderbilt University
School of Medicine; Staff Physician, Vanderbilt
University Hospital, Nashville, Tennessee
Current and Emerging Maintenance Immunosuppressive
Therapy

William E. Harmon, M.D.
Assistant Professor of Pediatrics, Harvard Medical
School; Director, Pediatric Nephrology, Children's
Hospital, Boston, Massachusetts
Pediatric Dialysis; Pediatric Transplantation

J. Harold Helderman, M.D.
Professor of Medicine, Microbiology, and Immunology,
Vanderbilt University School of Medicine; Staff
Physician, Vanderbilt University Hospital, Nashville,
Tennessee
Current and Emerging Maintenance Immunosuppressive
Therapy

Clifford J. Holmes, Ph.D.
Research Director, Baxter Healthcare Corporation,
McGaw Park, Illinois
Conventional and Newer Peritoneal Dialysis Solutions

Kathy Jabs, M.D.
Assistant Professor of Pediatrics, University of
Pennsylvania School of Medicine; Medical Director,
Renal Transplantation, Children's Hospital of
Philadelphia, Philadelphia, Pennsylvania
Pediatric Dialysis

Robert W. Jackman, Ph.D.
Principal Associate in Pathology, Harvard Medical
School; Research Associate, Department of Pathology,
Beth Israel Deaconess Medical Center, Boston,
Massachusetts
Peritoneal Membrane Biology

Toros Kapoian, M.D.

Assistant Professor of Medicine, University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School; Medical Director, Dialysis, Dialysis Clinic, Inc.—Robert Wood Johnson Dialysis Center, North Brunswick, and Robert Wood Johnson University Hospital, New Brunswick, New Jersey
Intradialytic Complications

Jonathan Kay, M.D.

Assistant Clinical Professor of Medicine, Harvard Medical School, Boston; Senior Staff, Section of Rheumatology, Lahey Clinic Medical Center, Burlington, Massachusetts
Dialysis-Related Amyloidosis

Ramesh Khanna, M.D., F.A.C.P.

Professor of Medicine, University of Missouri—Columbia School of Medicine; Associate Director, Division of Nephrology, University of Missouri—Columbia Hospitals and Clinics, Columbia, Missouri
Peritoneal Transport: Clinical Implications

Dicken S. C. Ko, M.D., F.R.C.S.(C.)

Instructor in Surgery and in Urology, Harvard Medical School; Assistant in Surgery and in Urology, Massachusetts General Hospital, Boston, Massachusetts
Surgical Aspects of Renal Transplantation

Alan M. Krensky, M.D.

Shelagh Galligan Professor, Department of Pediatrics, and Chief, Division of Immunology and Transplantation Biology, Stanford University School of Medicine, Stanford, California
Transplantation Immunobiology

Titus W. L. Lau, M.D.

Consulting Nephrologist, National Kidney Foundation of Singapore, Singapore.
Hemodialysis Adequacy

Jeffrey H. Lawson, M.D., Ph.D.

Assistant Professor of Surgery, Duke University School of Medicine, Durham, North Carolina
Xenotransplantation: Prospects for Clinical Application

Francisco Llach, M.D.

Professor of Medicine, UMDNJ—New Jersey Medical School; Chief of Nephrology, Newark Beth Israel Medical Center, Newark, New Jersey
Renal Osteodystrophy

Leo Martis, Ph.D.

Vice President, Baxter Healthcare Corporation, McGaw Park, Illinois
Conventional and Newer Peritoneal Dialysis Solutions

Michael A. Marx, Pharm.D., B.C.P.S.

Associate Professor, University of Arkansas College of Medicine (for Medical Sciences), Little Rock, Arkansas
Extracorporeal Treatment of Poisoning

Rosemary Masterson, M.B., B.Ch.

Fellow in Nephrology, St. Thomas' Hospital, London, England
Recurrent and De Novo Renal Disease in Kidney Transplantation

Dianne B. McKay, M.D.

Assistant Professor, Harvard Medical School; Associate Director of Renal Transplantation, Brigham and Women's Hospital, Boston, Massachusetts
Evaluation of Potential Renal Transplant Candidates and Donors

Ravindra L. Mehta, M.D.

Associate Professor of Medicine in Residence, University of California, San Diego, School of Medicine, and UCSD Medical Center, San Diego, California
Selection of Dialysis Modality

Edgar L. Milford, M.D.

Associate Physician, Harvard Medical School; Medical Director, Renal Transplantation, Brigham and Women's Hospital, Boston, Massachusetts
Evaluation of Potential Renal Transplant Candidates and Donors

Ronald Baker Miller, M.D., F.A.C.P.

Clinical Professor of Medicine, Director of the Program in Medical Ethics, and Former (and Founding) Chief of the Renal Division, University of California, Irvine, College of Medicine, Irvine, California
Ethical Issues in the Care of Patients with End-Stage Renal Disease Treated by Dialysis

Janice A. Nagy, Ph.D.

Assistant Professor of Pathology, Harvard Medical School; Research Associate, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Peritoneal Membrane Biology

Cynthia Nast, M.D.

Professor of Pathology, University of California, Los Angeles, UCLA School of Medicine; Attending Physician, Cedars Sinai Medical Center, Los Angeles, California
Diagnosis and Therapy of Graft Dysfunction

Douglas J. Norman, M.D., F.A.C.P.

Professor of Medicine; Director, Transplantation Medicine; and Director, Laboratory of Immunogenetics and Transplantation, Oregon Health Sciences University, Portland, Oregon
Induction Immunosuppressive Therapy

Yvonne M. O'Meara, M.D., F.R.C.P.I.

Senior Lecturer in Medicine, Department of Medicine and Therapeutics, University College Dublin; Consultant Nephrologist, Mater Misericordiae Hospital, Dublin, Ireland
Recurrent and De Novo Renal Disease in Kidney Transplantation

Henry Ooi, M.B., M.R.C.P.I.

Lecturer in Medicine, University College Dublin; Mater Misericordiae Hospital, Dublin, Ireland
Dopamine, Atrial Natriuretic Peptide, and Growth Factors in Acute Renal Failure

Rosemary Ouseph, M.D.

Assistant Professor of Medicine and Director, Organ Transplantation, University of Louisville School of Medicine, Louisville, Kentucky
Drug Dosing in Dialysis Patients

William F. Owen, Jr., M.D.

Director, Duke Institute of Renal Outcomes Research and Health Policy, Duke Clinical Research Institute, Division of Nephrology, Duke University Medical Center, Durham, North Carolina
Hemodialysis Adequacy

Patrick S. Parfrey, M.D., F.R.C.P.(C.)

University Research Professor, Memorial University of Newfoundland Faculty of Medicine; Chief, Clinical Epidemiology Unit, Memorial University Hospital and St. John's Hospital; Staff Nephrologist, Health Care Corporation of St. John's Hospital, St. John's, Newfoundland, Canada
Cardiac Disease in Dialysis Patients

V. Ram Peddi, M.D.

Assistant Professor of Medicine, University of Cincinnati College of Medicine; Attending Physician, University Hospital, Cincinnati, Ohio
Medical Complications of Kidney Transplantation

Brian J. G. Pereira, M.D.

Vice-Chairman, Department of Medicine, and Professor of Medicine, Tufts University School of Medicine; Staff Physician, Division of Nephrology, New England Medical Center, Boston, Massachusetts
Biocompatibility of Hemodialysis Membranes

Beth Piraino, M.D.

Professor of Medicine, University of Pittsburgh School of Medicine; Clinical Director, Renal Electrolyte Division; Program Director, Renal Fellowship Program; Director, Peritoneal Dialysis Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Management of Peritoneal Dialysis Infections

Jeffrey L. Platt, M.D., Ph.D.

Professor of Surgery, Immunology, and Pediatrics, Mayo Medical School and Mayo Clinic, Rochester, Minnesota
Xenotransplantation: Prospects for Clinical Application

Robert H. Rubin, M.D., F.A.C.P., F.C.C.P.

Gordon and Marjorie Osborne Chair of Health Sciences and Technology and Director of the Center for Experimental Pharmacology and Therapeutics, Harvard-M.I.T. Division of Health Sciences and Technology, Cambridge, Massachusetts; Chief, Surgical and Transplant Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts
Infection in the Renal Transplant Recipient

Mohamed H. Sayegh, M.D.

Associate Professor of Medicine, Harvard Medical School; Research Director, Laboratory of Immunogenetics and Transplantation, Brigham and Women's Hospital, Boston, Massachusetts
Transplantation Immunobiology

Steve J. Schwab, M.D.

Professor and Co-Director, Division of Nephrology, and Vice Chair, Department of Medicine, Duke University School of Medicine, Durham, North Carolina
Vascular Access for Hemodialysis

Mary Jo Shaver, M.D.

Instructor in Medicine, University of Arkansas College of Medicine (for Medical Sciences); Staff Physician, John L. McClellan Memorial Veterans Hospital, Little Rock, Arkansas
Extracorporeal Treatment of Poisoning

Richard A. Sherman, M.D.

Professor of Medicine, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School; Editor-in-Chief, Seminars in Dialysis, and Director, End-Stage Renal Disease Services, Robert Wood Johnson University Hospital, New Brunswick, New Jersey
Intradialytic Complications

Richard Solomon, M.D.

Associate Professor of Medicine, Harvard Medical School; Clinical Director, Beth Israel Deaconess Hospital and Joslin Diabetes Center, Boston, Massachusetts
Dopamine, Atrial Natriuretic Peptide, and Growth Factors in Acute Renal Failure

John C. Stivelman, M.D.

Associate Professor of Medicine, Emory University School of Medicine, Atlanta, Georgia
Achieving an Optimum Hematocrit

Amir Tejani, M.D.

Professor of Pediatrics and Surgery, New York Medical College, Valhalla, New York
Pediatric Renal Transplantation

Jerome I. Tokars, M.D., M.P.H.

Medical Epidemiologist, Centers for Disease Control and Prevention, Atlanta, Georgia
Nosocomial Infections in Hemodialysis Units: Strategies for Control

Nina E. Tolkoff-Rubin, M.D., F.A.C.P.

Associate Professor of Medicine, Harvard Medical School; Director of Dialysis and Medical Director of Renal Transplantation, Massachusetts General Hospital, Boston, Massachusetts
Infection in the Renal Transplant Recipient

Nicholas Topley, Ph.D.

Senior Lecturer in Cell/Molecular Biology, Institute of Nephrology, University of Wales College of Medicine, Cardiff Royal Infirmary, Cardiff, Wales, United Kingdom

Conventional and Newer Peritoneal Dialysis Solutions

David B. Van Wyck, M.D.

Associate Professor of Medicine, University of Arizona College of Medicine and Arizona Health Sciences Center, Tucson, Arizona

Achieving an Optimum Hematocrit

John P. Vella, M.D.

Instructor in Medicine, Harvard Medical School; Attending Physician, Brigham and Women's Hospital, Boston, Massachusetts

Current Results and Determinants of Graft Outcome in Kidney Transplantation

Richard A. Ward, Ph.D.

Professor of Medicine, Division of Nephrology, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky

Reprocessing of Hemodialyzers

Mark E. Williams, M.D., F.A.C.P.

Associate Clinical Professor of Medicine, Harvard Medical School; Director of Dialysis, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Management of the Diabetic Patient with End-Stage Renal Disease

Jay B. Wish, M.D.

Professor of Medicine and Coordinator, Patient-Based Program, Case Western Reserve University School of Medicine; Medical Director, Hemodialysis Services, University Hospitals of Cleveland, Cleveland, Ohio

Algorithms and Care Paths for Quality Improvement

Jane Y. Yeun, M.D.

Assistant Professor of Medicine and Director, Nephrology Fellowship Program, University of California, Davis, School of Medicine, Davis; Director, Acute Dialysis, Department of Veterans Affairs, Northern California Health Care System, Mather, California

Principles of Hemodialysis

Michael Yudd, M.D.

Assistant Professor of Medicine, UMDNJ-New Jersey Medical School; Medical Director, Dialysis Unit, Veterans Affairs New Jersey Health Care System, Newark, New Jersey

Renal Osteodystrophy

PREFACE

For the past two decades, *The Kidney*, by Drs. Barry M. Brenner and Floyd Rector, has been the central resource for authoritative and current information in the field of nephrology. However, the continuing expansion in the understanding of the pathophysiology and management of renal disease, dialysis, and transplantation and rapid advances in technology led to the need for more focused accompaniments to *The Kidney*. Consequently, Dr. Brenner planned on two additional textbooks—a concise and practical text on the treatment of renal disease and hypertension and a comprehensive textbook on dialysis and renal transplantation. The first such venture was *Therapy in Nephrology and Hypertension*, edited by Drs. Hugh R. Brady and Christopher Wilcox. Our textbook, *Dialysis and Transplantation*, is the second.

The intent of our venture was to provide readers with a seamless flow of information regarding the management of the patient with end-stage renal disease (ESRD). In pursuit of this goal, we sought to provide an overview of the principles of management of the patient with ESRD as well as a more focused examination of the physiologic principles and clinical application of the different modes of renal replacement therapy. We undertook this venture with the understanding that the treatment of patients with ESRD is complex and the field is rapidly changing. The past decade has witnessed new frontiers in the understanding of the physiologic basis of dialysis and its complications and of the immunologic basis of allograft tolerance and rejection. Advances in pharmaceutical technology and biotechnology have brought new and effective hormones and immunosuppressive agents into clinical use. In addition, the evolution of dialysis technology continues at a rapid pace. Finally, the continuing efforts of professional societies to improve the quality of patient care have resulted in the development of evidence-based clinical practice guidelines and clinical performance measures. These developments have mandated a new look at the management of the patient with ESRD. Consequently, we invited distinguished scientists and educators in the fields of hemodialysis, peritoneal dialysis, critical care nephrology, and transplantation to provide an in-depth review—from the laboratory to the clinic. Each author was challenged to discuss the fundamental concepts behind the management of the patient with ESRD, to provide a comprehensive critique of clinical trials, and to present rational recommendations for clinical treatment.

Our strategy was to cover the most clinically relevant issues in dialysis and transplantation and to classify them under six broad sections—principles and practice of hemodialysis, principles and practice of peritoneal dialysis, long-term care of the dialysis patient, renal replacement therapy in the critically ill, ethical issues, and kidney transplantation. Each section was overseen by one of the editors and included a brief overview of fundamentals of each modality of renal replacement therapy, followed by topics that were critically important for the optimal management of the ESRD patient. Each chapter is self-contained and provides the reader with a thorough review of the subject along with a complete list of key references. Diagnostic and treatment algorithms have been used whenever possible. With an eye on the future, our contributors were encouraged to identify major unanswered questions, to suggest future clinical trials, and to highlight promising experimental strategies. We have applied a strong editorial policy to ensure that chapters remain balanced and that they conform to these principles.

In summary, we have used the parent textbook, Brenner and Rector's *The Kidney*, and our sister textbook, Brady and Wilcox's *Therapy in Nephrology and Hypertension*, as the springboard for a bench-to-bedside review of the management of patients with ESRD. Readers are encouraged to refer to the previous two textbooks in this family for a detailed

discussion of other issues in nephrology. We intend to maintain this textbook as a work in progress and to update it periodically as the relentless advances in the field of dialysis and transplantation mandate. During the coming years, we welcome comments, critiques, and suggestions from our readers as we strive to deliver a comprehensive and contemporary textbook on dialysis and transplantation.

WILLIAM F. OWEN, JR.
BRIAN J. G. PEREIRA
MOHAMED H. SAYEGH




FIGURE 14-11. Color photomicrographs showing representative features of renal osteodystrophy. *A*, Normal trabecular bone. Mineralized bone matrix is stained blue; there is little unmineralized osteoid. (Undecalcified, modified Masson stain; original magnification $\times 100$.) *B*, Osteitis fibrosa in renal failure. There is an excess of unmineralized osteoid, which is stained red and lined by osteoblasts, and numerous multinucleate osteoclasts are present. Note that marrow fibrosis is evident. (Undecalcified, modified Masson stain; original magnification $\times 100$.) *C*, Osteomalacia with wide osteoid seams (red-staining material) in a patient with renal failure. (Undecalcified, modified Masson stain; original magnification $\times 100$.) *D*, Low-power view of cortical and trabecular bone in a patient with long-standing renal failure and osteosclerosis. There is a loss of distinction between cortical and trabecular bone and wide osteoid seams are present (red material). The periosteum can be seen in the upper right corner. (Undecalcified, modified Masson stain; original magnification $\times 40$.) *E*, Low-power view of trabecular bone stained for Al. The Al stains as a bright red band at the junction between mineralized bone (the pale blue in the center) and wide osteoid seams (paler area surrounding the bone). In this patient with Al-related osteomalacia, nearly all the forming surface is positive for Al. (Undecalcified, modified aluminum stain according to Maloney et al.) *F*, Higher-power views of two separate bone biopsy specimens from patient on dialysis who had Al-related osteomalacia before (left) and after (right) chelation therapy with weekly infusions of deferoxamine. Before therapy, there are widened osteoid seams (red) surrounding mineralized bone (blue). After therapy, there is a marked reduction in the osteoid thickness, and there is the appearance of peritrabecular fibrosis. Normal marrow elements are seen to the right of the trabeculum. (Undecalcified Goldner stain; original magnification $\times 160$.) Except for the area shown in *B*, these figures show findings similar to those labeled in black and white in Figure 15-10. (*A-D*, and *F*, Courtesy of S. L. Teitelbaum. *E*, Courtesy of D. J. Sherrard.) (From Llach F, Bover J: Renal osteodystrophy. In Brenner BM [ed]: Brenner & Rector's The Kidney, 5th ed. Philadelphia, WB Saunders, 1996, pp 2187-2274.)



FIGURE 25–2. Computer model of HLA (A) class I (HLA-B27) and (B) class II (HLA-DR1) structures. The peptide-binding region, made up of two α helices supported by a floor of β strands, is at the top of both views. For HLA-B27, α_1 domain is yellow, α_2 domain is blue, α_3 domain is green, and β_2 microglobulin is red. For HLA-DR1, the α_1 domain is yellow, α_2 domain is red, β_1 domain is blue, and β_2 domain is green. The colors are the same for homologous domains in the two proteins. (From Germain R: MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. *Cell* 1994; 76:288.)




FIGURE 25–3. Peptide binding to HLA class I (HLA-A2) (A) and class II (HLA-DR1) (B). The view is looking down on the molecule as a T lymphocyte might “see” it. The two α helices forming the rim of the peptide binding site are blue, and electron densities corresponding to bound peptides are shown in red. (A from Bjorkman PJ, Saper MA, Samraoui B, et al: Structure of the human class I histocompatibility antigen, HLA-A2. *Nature* 1987; 329:506; B from Brown JH, Jardetzky TS, Gorga JC, et al: Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. *Nature* 1994; 364:35.)




FIGURE 28-8. Pediatric en bloc kidneys. (From Shapiro R: Renal transplantation. *In* Starzl TE [ed]: Atlas of Organ Transplantation. Philadelphia, JB Lippincott, 1992, p 4.11.)